Literature DB >> 9631452

Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling.

M Brockhaus1, J Grünberg, S Röhrig, H Loetscher, N Wittenburg, R Baumeister, H Jacobsen, C Haass.   

Abstract

The Alzheimer's disease (AD) associated presenilin (PS) proteins are proteolytically processed. One of the processing pathways involves cleavage by caspases. Pharmacological inhibition of caspases is currently being discussed as a treatment for a variety of neurodegenerative diseases, including AD. We therefore inhibited caspase mediated processing of PS-1 and PS-2 in cells transfected with wt and mutant PS by mutagenizing the substrate recognition site or by using specific peptide aldehydes known to block caspases. We found that the inhibition of caspase mediated processing of PS proteins does not decrease its amyloidogenic activity. PS cDNA constructs with mutations in the caspase cleavage site are biologically active in Caenorhabditis elegans such as the wt human PS proteins, demonstrating that caspase-mediated cleavage is not required for the physiological PS function in NOTCH signaling.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9631452     DOI: 10.1097/00001756-199805110-00043

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  13 in total

Review 1.  Metabolism of presenilins.

Authors:  G Thinakaran
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

2.  The dynamics of Aβ distribution after γ-secretase inhibitor treatment, as determined by experimental and modelling approaches in a wild type rat.

Authors:  Leon M Tai; Helmut Jacobsen; Laurence Ozmen; Alexander Flohr; Roland Jakob-Roetne; Antonello Caruso; Hans-Peter Grimm
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-04-06       Impact factor: 2.745

3.  Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization.

Authors:  Luise Richter; Lisa-Marie Munter; Julia Ness; Peter W Hildebrand; Muralidhar Dasari; Stephanie Unterreitmeier; Bruno Bulic; Michael Beyermann; Ronald Gust; Bernd Reif; Sascha Weggen; Dieter Langosch; Gerd Multhaup
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

4.  Limited Effects of Prolonged Environmental Enrichment on the Pathology of 5XFAD Mice.

Authors:  Melanie Hüttenrauch; Susanne Walter; Margie Kaufmann; Sascha Weggen; Oliver Wirths
Journal:  Mol Neurobiol       Date:  2016-10-12       Impact factor: 5.590

Review 5.  Alzheimer's disease.

Authors:  Dennis J Selkoe
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

6.  Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.

Authors:  Helmut Jacobsen; Laurence Ozmen; Antonello Caruso; Robert Narquizian; Hans Hilpert; Bjoern Jacobsen; Dick Terwel; An Tanghe; Bernd Bohrmann
Journal:  J Neurosci       Date:  2014-08-27       Impact factor: 6.167

7.  Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons.

Authors:  W G Annaert; L Levesque; K Craessaerts; I Dierinck; G Snellings; D Westaway; P S George-Hyslop; B Cordell; P Fraser; B De Strooper
Journal:  J Cell Biol       Date:  1999-10-18       Impact factor: 10.539

8.  Potent and Selective BACE-1 Peptide Inhibitors Lower Brain Aβ Levels Mediated by Brain Shuttle Transport.

Authors:  Nadine Ruderisch; Daniel Schlatter; Andreas Kuglstatter; Wolfgang Guba; Sylwia Huber; Carlo Cusulin; Jörg Benz; Arne Christian Rufer; Joerg Hoernschemeyer; Christophe Schweitzer; Tina Bülau; Achim Gärtner; Eike Hoffmann; Jens Niewoehner; Christoph Patsch; Karlheinz Baumann; Hansruedi Loetscher; Eric Kitas; Per-Ola Freskgård
Journal:  EBioMedicine       Date:  2017-09-07       Impact factor: 8.143

9.  Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.

Authors:  Leopoldo Luistro; Wei He; Melissa Smith; Kathryn Packman; Maria Vilenchik; Daisy Carvajal; John Roberts; James Cai; Windy Berkofsky-Fessler; Holly Hilton; Michael Linn; Alexander Flohr; Roland Jakob-Røtne; Helmut Jacobsen; Kelli Glenn; David Heimbrook; John F Boylan
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

10.  Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment.

Authors:  M Brendel; A Jaworska; J Herms; J Trambauer; C Rötzer; F-J Gildehaus; J Carlsen; P Cumming; J Bylund; T Luebbers; P Bartenstein; H Steiner; C Haass; K Baumann; A Rominger
Journal:  Mol Psychiatry       Date:  2015-06-09       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.